Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price vs UIS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at UIS's multiple
Needs UIS P/S.
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · UIS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ROIVANT SCIENCES LTD. · implied price per share
Bear
$4.51
Base
$5.30
Bull
$6.10
Unisys Corp · implied price per share
Bear
-$27.92
Base
-$32.85
Bull
-$37.77
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.10x
-0.87x
Net debt / EBITDA
Leverage against operating earnings
32.78x
1.03x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$413.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
DXC Technology Co
ROIV vs DXC
Science Applications International Corp
ROIV vs SAIC
COGNIZANT TECHNOLOGY SOLUTIONS CORP
ROIV vs CTSH
GRID DYNAMICS HOLDINGS, INC.
ROIV vs GDYN
$442.59M
$246.50M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ROIV can rapidly improve revenue scale and margins from today’s deeply negative levels, then hold off on using UIS-implied value as a hard anchor because the current output is mechanically distorted by the input data; otherwise, the current price looks difficult to justify versus UIS on every stated relative multiple.
On the provided P/S framework, ROIV’s implied price is $0.00 versus a current price of $35.15, which shows an extreme apparent overvaluation versus UIS. However, UIS-derived output is mechanically driven by the valuation inputs and ROIV’s unusual financial profile, so the gap should be interpreted cautiously.
Supporting Metrics
